Categories
Health Markets

Akorn, Inc. (NASDAQ:AKRX) received warning letter from the Food and Drug Administration

Akorn, Inc. (NASDAQ:AKRX) said that it received a warning letter from the Food and Drug Administration related to the inspection of its Somerset, New Jersey manufacturing facility in July and August 2018. Akorn said it is committed to the highest standards of quality and compliance and will continue to work collaboratively with the FDA to resolve issues addressed in the warning letter.

Akorn, Inc. (NASDAQ:AKRX) shares fell -1.69% to finally closed at $4.65 in last active session. 

AKRX’s distance from 20 day simple moving average is 7.93% and distance from 50-Day simple moving average is 20.83%.

Analyst’s mean target price for AKRX is $6.60 while analysts mean recommendation is 2.70. Stock value has moved between $2.64 – 19.38 in last one year. Stock has got OUTPERFORM rating from 2 of Thomson Reuters analysts, 6 given HOLD rating to the stock and 0 given UNDERPERFORM rating. Analyst’s mean target price for AKRX is $6.60 while analysts mean recommendation is 2.70. 

Akorn, Inc. (NASDAQ:AKRX) yearly performance is -70.99%. Annual EPS Growth of past 5 years is -55.30%. The current share price indicates that stock is -76.34% away from its one year high and is moving 76.14% ahead of its 52-week low. 



On 25 June 2018, Newell Brands Inc. (NASDAQ:NWL) shares edged up 0.81% and ultimately finalized to $14.85 in last traded day. Stock has got OUTPERFORM rating from 0 of Thomson Reuters analysts, 10 given HOLD rating to the stock and 0 given UNDERPERFORM rating. Analyst’s mean target price for NWL is $19.33 while analysts mean recommendation is 2.80. 



At the movement Freeport-McMoRan Inc. (NYSE:FCX) is under coverage by number of analysts. Buy rating has been given by 2 analysts to the company stock whereas 2 given UNDERPERFORM rating to stock and {16} given HOLD rating. The consensus recommendation by Thomson Reuters analysts is 0.11 and their mean rating for the stock is 2.67 on scale of 1-5. Analysts mean target price for Freeport-McMoRan Inc. (NYSE:FCX) is $14.50 while their mean recommendation is 2.70 (1=Buy, 5=sell). 

If we look at stock performance in last active day trading, we see that stock has moved remains unchanged to end the day at $11.34. The current share price indicate that stock is -37.47% away from its one year high and is moving 19.70% ahead of its 52-week low. 

Leave a Reply